Thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-07 and is reviewed periodically as new material appears.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Methionine synthase reductase, also known as MSR, is an enzyme in humans that is encoded by the M1T3R gene. It functions as the obligate reductase for methionine synthase and restores its cofactor to an active state allowing it to sustain folate and methionine metabolosis.
We were only supposed to carry four passengers ... We had six." According to Maluțan, it was 12:08 when they left for Snagov. After they arrived there, Ceaușescu took Maluțan into the presidential suite and ordered him to get two helicopters filled with soldiers for an armed guard, and a further Dauphin to come to Snagov. Maluțan's unit commander replied on the phone, "There has been a revolution ... You are on your own ... Good luck!" Maluțan then said to Ceaușescu that the second motor was now warmed up and they needed to leave soon but he could only take four people, not six. Mănescu and Bobu stayed behind. Ceaușescu ordered Maluțan to head for Titu. Near Titu, Maluțan says that he received the national flights denial and had to land to not get shot down by the army. He did so in a field next to the old road that led to Pitești. Maluțan then told his four passengers that he could do nothing more. The Securitate men ran to the roadside and began to flag down passing cars. Two cars stopped, one of them driven by a forestry official and one a red Dacia driven by a local doctor. However, the doctor was not happy about getting involved and, after a short time driving the Ceaușescus, faked engine trouble. A bicycle repairman was then flagged down and drove them in his car to Târgoviște. The repairman, Nicolae Petrișor, convinced them that they could hide in an agricultural technical institute on the edge of town. When they arrived, the director there guided the Ceaușescus into a room and then locked them in.
== Former supermarket chains == Carrefour (Taken over by AEON Group to become AEON BiG) Emporium Supermarket & Departmental Store Fajar Supermarket Hiong Kong Supermarket Jaya Supermarket Kimisawa Supermarket Makro (Taken over by Tesco to become Tesco Extra) Ngiu Kee Pasaraya Greatwall Pasaraya Ocean Rich Supermarket Senyum Supermarket Costco Sri Kota Supermarket Tesco (Taken over by Lotus's) Tesco Extra Tops Yaohan Supermarket Kedai Runcit Usaha Kami Yuyi Supermarket
Sources: en.wikipedia.org
Triglycerides stored in adipose tissue and in other tissues, such as muscle and liver, release fatty acids and glycerol in a process known as lipolysis. Fatty acids are slower than glucose to convert into acetyl-CoA, as first it has to go through beta oxidation. It takes about 10 minutes for fatty acids to sufficiently produce ATP. Fatty acids are the primary fuel source at rest and in low to moderate intensity exercise. Though slower than glucose, its yield is much higher. One molecule of glucose produces through aerobic glycolysis a net of 30-32 ATP; whereas a fatty acid can produce through beta oxidation a net of approximately 100 ATP depending on the type of fatty acid. For example, palmitic acid can produce a net of 106 ATP.
The base peak chromatogram is similar to the TICC, however it monitors only the most intense peak in each spectrum. This means that the base peak chromatogram represents the intensity of the most intense peak at every point in the analysis. Base peak chromatograms often have a cleaner look and thus are more informative than TIC chromatograms because the background is reduced by focusing on a single analyte at every point.
In 2000, it acquired Brazilian appliance maker Multibrás, owner of the brands Brastemp and Consul, including its stake in Embraco. In 2001, Inglis Ltd. changed its name to Whirlpool Canada. Whirlpool continues to market Inglis appliances to this day.
=== Mare === In 2016, Cave completed the Massachusetts Institute of Technology's Global Entrepreneurship Bootcamp and developed an oil spill dispersant molecule, raising US$1.2 million in funding from Chevron for further research. She became the co-founder of Mare, a research initiative dedicated to developing solutions to large-scale problems. In 2017, Cave was included on the Forbes 30 Under 30 list and Magic Johnson's 32 Under 32 list. In 2018, Cave was named one of Glamour Magazine's 2018 College Women of the Year. Cave was named to Entrepreneur Magazine's 2018 Young Millionaires List, following the acquisition of Mare in late 2017.
Sources: en.wikipedia.org
During the COVID-19 pandemic, Pritzker took several measures to mitigate the pandemic in Illinois. On March 13, 2020, Pritzker declared that public and private schools in Illinois would be closed from March 17 through March 31. On March 15, he announced that all bars and restaurants must close until March 30. Restaurant businesses with delivery and takeout options would still be able to serve. On March 16, 2020, Pritzker issued an executive order limiting permitted crowd sizes to 50 people. Despite pressure from Chicago election officials, he refused to postpone the state's March 17 primary elections, since it was not something that he had the authority to do. On March 20, 2020, Pritzker issued a stay-at-home order to take effect the next day. Under this order, all non-essential businesses were required to close while essential businesses such as grocery stores, gas stations, hospitals, pharmacies remained open. The order originally ended on April 8. The state government coordinated a public health response. The State of Illinois worked with the U.S. Department of Health and Human Services, Wal-Mart, and Walgreens to provide testing sites in Illinois's hardest-hit communities. By June, amid unrest by some municipalities unhappy with Pritzker's lockdown orders, Mayor Keith Pekau of Orland Park, a suburb southwest of Chicago, and a local restaurateur sued Pritzker in federal court, alleging that the lockdown orders violated state law and the state constitution. U.S. District Judge Andrea Wood ruled against the plaintiffs, allowing the lockdown orders to stay in place.
3 CO2 + 6 NADPH + 6 H+ + 9 ATP + 5 H2O → TP + 6 NADP+ + 9 ADP + 8 Pi The formula for inorganic phosphate (Pi) is HOPO32− + 2 H+.Formulas for triose and TP are C2H3O2-CH2OH and C2H3O2-CH2OPO32− + 2 H+.
== Benign neoplasms (210–229) == 210 Benign neoplasm of lip, oral cavity, and pharynx 211 Benign neoplasm of other parts of digestive system 211.3 Colon Familial adenomatous polyposis 212 Benign neoplasm of respiratory and intrathoracic organs 212.0 Nasal cavities middle ear and accessory sinuses 212.1 Larynx 212.2 Trachea 212.3 Bronchus and lung 212.4 Pleura 212.5 Mediastinum 212.6 Thymus 212.7 Heart Myxoma Rhabdomyoma 213 Benign neoplasm of bone and articular cartilage 213.9 Bone and articular cartilage, site unspecified Chondroma 214 Lipoma 215 Other benign neoplasm of connective and other soft tissue 216 Benign neoplasm of skin Melanocytic nevus 217 Benign neoplasm of breast 218 Uterine leiomyoma 219 Other benign neoplasm of uterus 220 Benign neoplasm of ovary 221 Benign neoplasm of other female genital organs 222 Benign neoplasm of male genital organs 223 Benign neoplasm of kidney and other urinary organs 224 Benign neoplasm of eye 225 Benign neoplasm of brain and other parts of nervous system 226 Benign neoplasm of thyroid glands 227 Benign neoplasm of other endocrine glands and related structures 228 Hemangioma and lymphangioma, any site 228.0 Hemangioma, any site 228.1 Lymphangioma, any site 229 Benign neoplasm of other and unspecified sites
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.